GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study

BACKGROUND: Pre-clinical data have suggested a therapeutic role of Hedgehog (Hh) pathway inhibitors in chondrosarcoma. METHODS: This phase II trial included patients with progressive advanced chondrosarcoma. They received GDC-0449 150 mg/day (days 1–28, 28-day cycle). The primary end point was the 6...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Italiano, A., Le Cesne, A., Bellera, C., Piperno-Neumann, S., Duffaud, F., Penel, N., Cassier, P., Domont, J., Takebe, N., Kind, M., Coindre, J.-M., Blay, J.-Y., Bui, B.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2013
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3811907/
https://ncbi.nlm.nih.gov/pubmed/24170610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt391
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky